Wayne Kuznar
Wayne Kuznar is a contributor to Urology Times.
Glypican-1 shows promise as prostate cancer biomarker
The cell surface amino acid glypican-1 (GPC-1) represents a potential new biomarker for prostate cancer, said Jonathan Henderson, MD, at the AUA annual meeting.
Biomarkers yet to fully justify claimed clinical utility
Biomarker models to predict disease progression in prostate cancer have a promising future, but at present, they have not fully justified their claimed clinical utilities, according to the authors of an independent review and analysis of the literature.
Statins may improve prostate cancer outcomes
Statins may improve outcomes in hormone-sensitive prostate cancer, and one possible mechanism responsible may have been discovered.
Second mCRPC agent shows significant benefit pre-chemo
Abiraterone acetate (ZYTIGA) as therapy for chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) improved overall survival by a statistically significant 19% compared with placebo in the final analysis of the phase III COU-AA-302 clinical trial.
Second agent shows significant benefit in mCRPC pre-chemo
Abiraterone acetate (ZYTIGA) as therapy for chemotherapy-naïve metastatic castration-resistant prostate cancer improved overall survival by a statistically significant 19% compared with placebo in the final analysis of the phase III COU-AA-302 clinical trial.
How ‘low risk’ is low-risk prostate cancer?
As it becomes apparent that more prostate cancers are clinically insignificant than previously believed, the role of active surveillance in the management of men with low-risk prostate cancer merits expansion.
Upfront chemo plus ADT dramatically improves survival
A new study showing a survival benefit of more than 1 year with a chemotherapy-hormonal therapy combination given prior to castration resistance is being hailed by a leading prostate cancer expert as possibly representing a “new standard” in care.
Prostate EBRT linked with risk of two other cancers
Men with prostate cancer who are treated with external beam radiation therapy are at an increased risk for cancer of the bladder and rectum 10 years or more after their prostate cancer diagnosis, according to an analysis using data from the Surveillance, Epidemiology, and End Results program.
Focal therapy: Magic bullet or unproven treatment?
Focal therapy has been promoted as a minimally morbid option for men with localized low-risk prostate cancer who nevertheless want their disease treated. Opponents of focal therapy note the heterogeneity and multifocal nature of prostate cancer, the difficulty of accurately targeting and destroying an index tumor with focal therapy, and the unknown biologic potential of the tumor.
Higher PSA density linked to biopsy progression of prostate cancer
Higher PSA density at diagnosis is associated with biopsy progression of low-risk prostate cancer in patients enrolled in active surveillance.

Poll

View Results